{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
amphotericin b
to a specific field?
Status:
Investigational
Source:
NCT00712725: Phase 2 Interventional Completed Migraine
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
MK-3207 represents the third CGRP receptor antagonist to display clinical efficacy in migraine trials. It is a potent CGRP receptor antagonist with IC50 and Ki of 0.12 nM and 0.022 nM, highly selective versus human AM1, AM2, CTR, and AMY3. MK-3207 had been in phase II clinical trials by Merck Sharp & Dohme for the treatment of migraine. But the company had discontinued the research due to asymptomatic liver test abnormalities in 2010.
Class (Stereo):
CHEMICAL (ACHIRAL)
Isoxepac (also known) as HP-549 is a non-steroidal anti-inflammatory drug with analgesic activity. Isoxepac was studied in the clinical trial for the treatment of postoperative pain after knee surgery for meniscectomy. It was shown, that 200 mg of isoxepac would appear to be the minimal effective dose. In case of rheumatoid arthritis, isoxepac showed significantly fewer adverse effects.
Class (Stereo):
CHEMICAL (ABSOLUTE)
KALAFUNGIN is an antimicrobial agent obtained from the culture broth of a soil isolate of Streptomyces tanashiensis, designated Streptomyces tanashiensis strain Kala UC-5063. It has in vitro activity against a variety of pathogenic fungi, yeasts, protozoa, and bacteria.
Class (Stereo):
CHEMICAL (ACHIRAL)
Fluradoline (also known as HP-494), a centrally acting antinociceptive agent with antidepressant properties. Experiments on rodents have shown that fluradoline blocked the reuptake of NE, 5-HT, and DA in the brain. Besides, fluradoline was studied for the prevention of acute and chronic postsurgical pain.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Anatibant was a selective small-molecule antagonist of the bradykinin B2 receptor that was undergoing clinical development with Xytis and Fournier for the treatment of brain injuries. Anatibant reduces brain oedema in animal TBI models. Noserious toxicity was found in Phase 1 clinical trials. Following subcutaneous administration of clinically relevant doses, there were no systemic effects but there was pain, inflammation and nodule formation at the injection site. Anatibant inhibits the binding of BK to the B2 receptor. After subcutaneous injection Anatibant is bio-available and crosses the BBB.
Status:
Investigational
Source:
J Zoo Wildl Med. Sep 2016;47(3):834-843.: Not Applicable Veterinary clinical trial Completed N/A
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Etorphine was the first potent opiate agonist employed primarily for use in non-domestic and wild species. Etorphine was 500 times as potent as morphine, with a very rapid onset and short duration of action. In morphine-dependent subjects, etorphine suppressed abstinence but for a shorter period than morphine. Etorphine is a full opiate agonist and binds to multiple opiate sites in the central nervous system. It is believed to produce its clinical effects through binding the µ-, δ-, and κ- opiate sites. It has a potent effect on depressing the respiratory centers of the CNS thus resulting in apnea being commonly seen in immobilized animals. Etorphine revolutionized the ability of biologists and veterinarians to safely capture and restrain many species that previously could not be handled. Etorphine is not currently commercially available due to lack of production by the manufacturer.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Hydromorphinol, an opioid, and is a derivative of morphine and possesses similar properties: sedation, analgesia, and respiratory depression. Hydromorphinol is under the control according to US Single Convention 1961.
Status:
Investigational
Source:
NCT00780663: Phase 2 Interventional Completed Neuroendocrine Tumors
(2008)
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Quarfloxin (also known as CX-3543) is a fluoroquinolone derivative patented by Cyclene Pharmaceuticals, Inc. as an antitumor agent. Quarfloxin selectively disrupts nucleolin/rDNA G-quadruplex complexes in the nucleolus, thereby inhibiting DNA polymerase I transcription and inducing apoptosis in cancer cells. CX-3543 was evaluated in phase II clinical studies for the treatment of low or intermediate grade neuroendocrine carcinoma, including carcinoid and islet cell cancer. In 2008, a trial for the treatment of chronic lymphocytic leukemia (CLL) was withdrawn prior to patient enrollment. In 2010, phase I clinical studies for the treatment of solid tumors and for the treatment of lymphoma were terminated upon the observation that the modified dose schedule presented no advantage over previously studies schedule solid tumors/ Cylene discontinued development of quarfloxin in 2010.
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Actinoquinol is sunscreen agent that absorbs Ultraviolet B light. Actinoquinol in combination with hyaluronic acid drops might be helpful for the human eye in the defense against photooxidative and other oxidative processes.
Status:
Investigational
Source:
NCT01239108: Phase 1 Interventional Withdrawn Relapsed/Refractory Leukemias
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
SGI-1776 is a PIM-kinase inhibitor, developed by SuperGen Inc. SGI-1176 was tested in clinical trials against relapsed/refractory leukemias, prostate cancer and Non Hodgkin's Lymphoma, but the dose limiting toxicity of cardiac QTc prolongation was identified and clinical development of SGI-1776 was terminated.
